Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 6Thoracic 3Other solid neoplasm 3Tumor-Agnostic 2Plasma cell 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × pevonedistat × Tumor-Agnostic × Clear all
NCT04800627 2022-12-27

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

M.D. Anderson Cancer Center

Phase 1/2 Terminated
2 enrolled 4 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
8 enrolled 26 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡